This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Nevro's (NVRO) Latest Buyout to Boost SI Joint Pain Treatment
by Zacks Equity Research
Nevro's (NVRO) latest acquisition is likely to bring long-term pain relief to people suffering from chronic low back pain associated with the SI joint.
Wall Street Analysts Predict a 36.66% Upside in Nevro (NVRO): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Nevro (NVRO) points to a 36.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Nevro's (NVRO) New Data Supports SCS Therapy for NSRBP Treatment
by Zacks Equity Research
Nevro's (NVRO) latest 24-month data demonstrates the benefits of high-frequency 10 kHz SCS therapy for lasting pain relief, enhanced function, quality of life and reduced opioid dependency.
Nevro (NVRO) Q3 Earnings Top Estimates, FY23 Revenue View Up
by Zacks Equity Research
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in the third quarter, owing to robust domestic performance.
Nevro (NVRO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Nevro (NVRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nevro's (NVRO) New Data Supports SCS Therapy for PDN Treatment
by Zacks Equity Research
Nevro's (NVRO) latest 24-month data demonstrates the benefits of high-frequency 10 kHz SCS implant for durable pain relief and significant improvements in patient condition post-implantation.
Nevro's (NVRO) Latest Launch to Customize Chronic Pain Treatment
by Zacks Equity Research
Nevro's (NVRO) HFX Connect system is expected to treat individual patients per their requirements with 35 pre-programmed customizable plans.
Nevro (NVRO) Q2 Earnings Lag Estimates, FY23 View Cut
by Zacks Equity Research
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in the second quarter owing to robust domestic and international performances.
Nevro (NVRO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Nevro (NVRO) delivered earnings and revenue surprises of -1.47% and 0.48%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks to Watch for Earnings on Aug 1: ECL, NVRO, INSP
by Debanjana Dey
MedTech companies' Q2 results are likely to reflect strength in customer demand. Let's see how ECL, NVRO and INSP are placed ahead of their earnings releases.
Integer (ITGR) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of 15.15% and 8.99%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO) due to its R&D edge.
Why Is OPKO Health (OPK) Down 17.2% Since Last Earnings Report?
by Zacks Equity Research
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nevro (NVRO) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q1, partly owing to robust domestic performance.
Nevro (NVRO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nevro (NVRO) delivered earnings and revenue surprises of 7.55% and 1.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Ecolab (ECL) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) first-quarter results are likely to reflect continued strength in its Global Industrial segment.
MedTech Stocks' Q1 Earnings Due on Apr 26: MMSI, CNMD & More
by Indrajit Bandyopadhyay
Medical Device players are expected to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how MMSI, CNMD, NVRO and ARAY are likely to have performed this time.
How Much Upside is Left in Nevro (NVRO)? Wall Street Analysts Think 53.7%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 53.7% in Nevro (NVRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Will OrthoPediatrics (KIDS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
OrthoPediatrics (KIDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nevro's (NVRO) Latest Launch to Customize Chronic Pain Treatment
by Zacks Equity Research
Nevro's (NVRO) Senza HFX iQ SCS system is expected to treat individual patients per their particular treatment requirements.
Nevro (NVRO) Q4 Earnings Lag Estimates, Revenues Beat
by Zacks Equity Research
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q4, partly owing to robust domestic performance.
Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nevro (NVRO) delivered earnings and revenue surprises of -10.20% and 0.52%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Masimo (MASI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for West Pharmaceutical (WST) in Q4 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) fourth-quarter results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements are likely to hurt the top and the bottom lines.
Will Nevro (NVRO) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.